Tesamorelin for HIV lipodystrophy: the FDA-approved indication, trial by trial.

Of the growth-hormone-axis peptides, only tesamorelin obtained FDA approval. The pivotal trials demonstrated visceral adipose tissue reduction in HIV-associated lipodystrophy — here is what that evidence base shows.

HIV-associated lipodystrophy is the syndrome that won tesamorelin its label. To understand why this peptide got FDA approval when CJC-1295 and ipamorelin didn't, we need to walk through what lipodystrophy is, why visceral fat is the dangerous kind, and why a GHRH analog turned out to fix it.

What is HIV-associated lipodystrophy?

It's a body-composition syndrome with two simultaneous changes. Visceral adipose tissue (VAT) — the fat depot surrounding the intra-abdominal organs — accumulates. Subcutaneous fat — the fat in the extremities and face — is lost. The resulting phenotype (round abdomen, thin limbs, sunken cheeks) was first described in the late 1990s as a complication of older protease-inhibitor antiretroviral regimens, especially stavudine and zidovudine.

The clinical problem is not merely cosmetic. Visceral fat is metabolically active and has been linked to cardiometabolic risk: insulin resistance, abnormal cholesterol, fatty liver, and higher cardiovascular event rates. Epidemiological studies have reported cardiovascular disease and type 2 diabetes at significantly higher rates in HIV research subjects with lipodystrophy versus those without it, even after adjusting for other risk factors. Reducing visceral fat in this population has therefore been investigated as a strategy to attenuate cardiometabolic morbidity.

Contemporary first-line HIV therapy looks different. Integrase-strand-transfer inhibitors (INSTIs) like dolutegravir dominate current prescribing. They don't cause the classic peripheral-fat loss the older drugs did. But observational data link them to weight gain and visceral fat accumulation, especially in women and Black patients. That's why the 2024 sub-analysis in INSTI-treated patients matters: the labeled indication is now being applied to a slightly different lipodystrophy pattern than the original trials studied.

The pivotal trials — what the FDA approved

The FDA approval rested on two large randomized double-blind placebo-controlled Phase III trials. Both enrolled HIV patients meeting clinical criteria for abdominal fat accumulation. The primary endpoint was visceral adipose tissue (VAT) measured by CT scan at the L4–L5 disc level at 26 weeks versus placebo.

The pooled result: 15–18% VAT reduction on tesamorelin vs. placebo. That's clinically meaningful by any reasonable standard. It translated to measurable improvements in waist circumference, trunk fat percentage, and IGF-1 elevation (showing the drug was doing what it should).

Critically, the effect was VAT-selective. Tesamorelin did not reduce subcutaneous fat, nor did it worsen the peripheral fat loss that already defines lipodystrophy. That selectivity underpins the mechanistic rationale for the labeled indication: the compound targets the visceral fat compartment implicated in cardiometabolic risk without compounding the peripheral fat loss already present in the study population.

Adverse events were mostly injection-site reactions, with smaller increases in joint pain, peripheral edema, and tingling sensations consistent with general GH-axis stimulation. Hyperglycemia (high blood sugar) occurred at higher rates than placebo. That's why the label contraindicates tesamorelin in poorly controlled diabetes.

Tesamorelin

Stabilized GHRH 44 aa FDA-approved

The same compound cited across the Phase III HIV lipodystrophy trials and the 2024 INSTI sub-analysis in this article. Lab-verified identity and purity.

View Tesamorelin

The 2019 SV reformulation

The 2019 FDA approval of Egrifta SV wasn't a new molecule. It was a formulation update. The SV (sterile vial) version delivers the same peptide in a more concentrated solution, dropping injection volume from roughly 2 mL to under 1 mL. Pharmacology, efficacy, and adverse events are unchanged. The rationale was adherence: a reduced-volume subcutaneous injection reduces the burden for long-term clinical use.

For study participants managing lipodystrophy long-term, administration burden is a recognized clinical variable in adherence research. The 2019 approval reflects Theratechnologies's investment in keeping the existing labeled population on therapy, not expanding into new indications.

The 2024 INSTI update

The Russo 2024 paper is one of the most clinically relevant recent tesamorelin studies. It's a sub-analysis of 38 patients on integrase-inhibitor regimens from a larger double-blind randomized trial. The analysis reported:

• Median VAT change: −25 cm² on tesamorelin vs. +14 cm² on placebo at L4–L5.
• Liver fat change: −4.2% on tesamorelin vs. −0.5% on placebo.
• Improvement in trunk-to-limb fat ratio.
• Hyperglycemia rates were comparable between groups (no worsening of glucose control specific to INSTI co-treatment).

Why this matters: INSTI-based regimens (dolutegravir, bictegravir, raltegravir) are first-line HIV therapy today. The patient population being managed in 2026 is largely on INSTIs. Observational data link INSTIs to weight gain and visceral fat accumulation, which doesn't fully match the older protease-inhibitor lipodystrophy pattern. Russo 2024 shows tesamorelin still works in this contemporary population.

Fat quality, not just fat quantity

A 2021 post-hoc analysis of 341 participants across the tesamorelin development program by Lake and colleagues showed something subtle. Tesamorelin increased VAT and SAT density on CT scans — a marker of healthier, smaller fat cells (adipocytes) — independent of changes in fat area.

Why this matters: two study participants with the same waist circumference can have very different adipose tissue physiology. One cohort may have hypertrophied, stressed adipocytes pumping out pro-inflammatory signals; another may have adipocytes storing lipids without driving inflammation. Tesamorelin appears to shift adipose biology toward the metabolically favorable pattern, not merely reduce fat quantity. The cardiometabolic benefit may therefore exceed what waist measurement alone predicts — the compound appears to change the nature of the adipose tissue, not only its volume.

Liver fat: the HIV-NAFLD trial

A 12-month randomized double-blind trial in 61 patients with HIV-associated nonalcoholic fatty liver disease (NAFLD) is the most-cited post-approval tesamorelin study. It showed reduced liver fat and prevention of fibrosis progression on paired liver biopsies. Secondary analyses have produced data on liver gene expression, plasma proteins, and immune activation markers (Fourman 2020, Stanley 2021, Fourman 2021).

The headline: tesamorelin's effects in HIV-NAFLD extend beyond simple liver-fat reduction to downregulation of inflammation, immune activation, and tissue-repair gene programs. Those are the same pathways implicated in NASH and MASLD progression. Whether those mechanisms translate to non-HIV NASH and MASLD populations is the research question driving pipeline expansion. We'll be watching readouts from the broader GHRH analog class closely.

Cost, coverage, and access reality

For all the science behind tesamorelin, real-world access is constrained. Retail price for Egrifta SV in the U.S. runs roughly $3,500–5,000 per month. Even with a covered indication, prior authorization and step therapy are common gatekeepers. Insurance coverage outside the labeled HIV lipodystrophy indication is essentially nonexistent. The drug isn't approved for non-HIV NAFLD, general visceral obesity, or body recomposition.

The result: real-world use is dominated by HIV patients with documented lipodystrophy. Off-label clinical use happens, mostly through compounding pharmacies, but the FDA's tightening of 503A compounding eligibility for GHRH peptides has narrowed even that channel. Research-grade tesamorelin sold for in-vitro work is a separate supply chain — fine for lab use, not a substitute for the FDA-approved drug in human contexts.

For comparison: HIV patients with coverage typically pay copays of $0–100 per month. Without coverage, they face a roughly 30–50x cost burden. That gap effectively requires insurance for sustained use.

Tesamorelin

10 mg ≥99% pure Lyophilized

44-aa stabilized GHRH analog. The same reference compound used across the cited Phase III pivotal trials. COA available with each lot.

Learn more

Tesamorelin in the HIV lipodystrophy treatment landscape (2026)

Published HIV-care guidelines and clinical trial protocols describe tesamorelin as the only FDA-approved pharmacologic agent that specifically addresses visceral fat accumulation in HIV-associated lipodystrophy. The reported clinical management sequence in the literature follows a stepwise approach:

• Antiretroviral regimen review — studies have described transitioning research subjects off older agents associated with lipodystrophy (stavudine, zidovudine, older protease inhibitors) toward contemporary INSTI-based regimens, balanced against the INSTI weight-gain data.
• Lifestyle intervention — published protocols position diet, exercise, and weight management as initial steps for visceral-fat-driven metabolic syndrome in HIV populations.
• Tesamorelin — investigated in study participants meeting clinical criteria for HIV lipodystrophy with persistent VAT accumulation after lifestyle and ART optimization. This represents the labeled indication for the approved drug.
• Comorbidity management — trials have run lipid-lowering, glucose-lowering, and antihypertensive interventions in parallel, treating tesamorelin as an upstream intervention on the fat compartment rather than a replacement for downstream comorbidity management.

The literature characterizes tesamorelin as an upstream intervention on the visceral fat compartment that drives cardiometabolic sequelae, rather than a substitute for managing the downstream conditions themselves.